ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

OMER Omeros Corporation

3.42
0.00 (0.00%)
Pre Market
Last Updated: 04:55:01
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 3.36
Ask Price 4.47
News -
Day High

Low
0.92

52 Week Range

High
7.7975

Day Low
Share Name Share Symbol Market Stock Type
Omeros Corporation OMER NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 3.42 04:55:01
Open Price Low Price High Price Close Price Previous Close
3.42
Trades Shares Traded Average Volume 52 Week Range
0 0 - 0.92 - 7.7975
Last Trade Type Quantity Price Currency
- 0 US$ 3.42 USD

Omeros Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
215M 62.87M - 0 47.42M 0.75 4.53
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Omeros News

Date Time Source News Article
3/27/202407:30Business WireOmeros Corporation to Announce Fourth Quarter and Year-End..
2/20/202408:00Business WireOmeros Corporation Announces Upcoming Presentation Detailing..
2/14/202405:05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial..
2/07/202407:00Edgar (US Regulatory)Form 8-K - Current report
2/01/202408:11Business WireOmeros Corporation Announces Additional Royalty Monetization..
1/29/202414:26Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial..
11/21/202319:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
11/17/202320:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
11/15/202320:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
11/09/202315:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/09/202315:05Edgar (US Regulatory)Form 8-K - Current report
11/09/202315:02Business WireOmeros Corporation Reports Third Quarter 2023 Financial..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No OMER Message Board. Create One! See More Posts on OMER Message Board See More Message Board Posts

Historical OMER Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week3.773.943.34023.48285,870-0.35-9.28%
1 Month4.494.853.34023.97411,957-1.07-23.83%
3 Months2.955.1352.763.89583,3760.4715.93%
6 Months2.935.1350.922.78721,1670.4916.72%
1 Year4.077.79750.923.82642,477-0.65-15.97%
3 Years19.0919.390.925.90784,318-15.67-82.08%
5 Years17.3225.490.929.40748,478-13.90-80.25%

Omeros Description

Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.

Your Recent History

Delayed Upgrade Clock